Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist

Eph receptors have emerged as targets for therapy in both neoplastic and non-neoplastic disease, however, particularly in non-neoplastic diseases, redundancy of function limits the effectiveness of targeting individual Eph proteins. We have shown previously that a soluble fusion protein, where the E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Pegg, Cassandra L., Cooper, Leanne T., Zhao, Jing, Gerometta, Michael, Smith, Fiona M., Yeh, Michael, Bartlett, Perry F., Gorman, Jeffrey J., Boyd, Andrew W.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5529513/
https://ncbi.nlm.nih.gov/pubmed/28747680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-06685-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados